[{"orgOrder":0,"company":"Citryll","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Citryll \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Inapplicable"},{"orgOrder":0,"company":"Citryll","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Subcutaneous Injection","sponsorNew":"Citryll \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Johnson & Johnson"},{"orgOrder":0,"company":"Citryll","sponsor":"ReumaNederland","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Citryll \/ ReumaNederland","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ ReumaNederland"},{"orgOrder":0,"company":"Citryll","sponsor":"Bom Brabant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citryll \/ Bom Brabant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Citryll \/ Bom Brabant Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Citryll

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Specialty & Agro Chemical
                          Not Confirmed
                          Specialty & Agro Chemical
                          Not Confirmed

                          Details : The financing will support the company-lead product CIT-013 monoclonal antibody. It is being evaluated for the treatment of rheumatoid arthritis.

                          Product Name : CIT-013

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          December 09, 2024

                          Lead Product(s) : CIT-013

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Johnson & Johnson

                          Deal Size : $89.2 million

                          Deal Type : Series B Financing

                          blank

                          02

                          Specialty & Agro Chemical
                          Not Confirmed
                          Specialty & Agro Chemical
                          Not Confirmed

                          Details : CIT-013 offers a novel therapeutic approach for treating inflammatory diseases by targeting NETs, which is being investigated for rheumatoid arthiritis.

                          Product Name : CIT-013

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          July 31, 2024

                          Lead Product(s) : CIT-013

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Specialty & Agro Chemical
                          Not Confirmed
                          Specialty & Agro Chemical
                          Not Confirmed

                          Details : The proceeds will be used in the clinical development programs of NET-targeting therapies such as Citryll’s lead anti-inflammatory candidate CIT-013, a first-in-class monoclonal antibody.

                          Product Name : CIT-013

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 10, 2024

                          Lead Product(s) : CIT-013

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : ReumaNederland

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          04

                          Specialty & Agro Chemical
                          Not Confirmed
                          Specialty & Agro Chemical
                          Not Confirmed

                          Details : The proceeds will be used to advance the pre-clinical and clinical development of Citryll’s CIT-013 therapeutic antibody, an inhibitor of neutrophil extracellular traps (NETs) and their formation (NETosis).

                          Product Name : CIT-013

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          February 07, 2020

                          Lead Product(s) : CIT-013

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Bom Brabant Ventures

                          Deal Size : $21.0 million

                          Deal Type : Financing

                          blank